{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T23:35:01Z","timestamp":1782430501452,"version":"3.54.5"},"reference-count":28,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"DiaMedica Therapeutics Inc., Minneapolis, MN."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Stroke"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Rinvecalinase alfa (DM199), a recombinant form of human tissue kallikrein-1 (KLK1), aims to promote local vasodilation to ischemic brain and enhance collateral blood flow. The ReMEDy1 trial tested the safety and tolerability of rinvecalinase alfa in ischemic stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>ReMEDy1 was a phase II, randomized, double-blind, placebo-controlled, study conducted at 13 Australian sites. Ninety-two patients with NIH Stroke Scale (NIHSS) 6\u201325 were enrolled within 24\u2009h of ischemic stroke onset. Patients were randomized 1:1 to receive rinvecalinase alfa (1\u2009\u00b5g\/kg intravenous infusion followed by 3\u2009\u00b5g\/kg subcutaneously every 3 days for 22\u2009days) or placebo. The primary outcome was safety, assessed by adverse events (AEs) and serious adverse events (SAEs). Secondary outcomes included changes in NIHSS, modified Rankin Scale (mRS), and Barthel Index (BI) at Days 22 and 90. Post hoc analyses excluded patients who underwent endovascular therapy (EVT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The median age was 72, NIHSS 10, and onset-to-randomization was 19.5\u2009h. SAEs were reported in 20\/47 (43.5%) rinvecalinase alfa patients and 14\/45 (31.1%) placebo patients. Most patients experienced at least one AE; the most common in the rinvecalinase alfa group were constipation (60.9%), oral candidiasis (23.9%), and nausea (17.4%). Stroke-in-evolution by Day 90 occurred in 0 (0%) rinvecalinase alfa patients versus 6 (13.3%) placebo patients; 4\/6 (66.7%) placebo patients with stroke-in-evolution died. No significant differences were observed in secondary efficacy outcomes at Day 90. Post hoc analyses in patients not treated with EVT suggested a tendency toward improved excellent global outcomes with rinvecalinase alfa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Rinvecalinase alfa appeared to be safe and generally well-tolerated in ischemic stroke patients, with potential efficacy in reducing stroke progression. Further studies are needed to confirm efficacy and long-term benefits in patients without EVT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registrations:<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT03290560\">https:\/\/www.clinicaltrials.gov\/study\/NCT03290560<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17474930251396480","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:42:00Z","timestamp":1762432920000},"page":"861-870","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and tolerability of Rinvecalinase Alfa (DM199) for acute ischemic stroke (ReMEDy1)"],"prefix":"10.1177","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3632-9433","authenticated-orcid":false,"given":"Bruce CV","family":"Campbell","sequence":"first","affiliation":[{"name":"Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia"},{"name":"The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia"},{"name":"Department of Neurology, The Royal Melbourne Hospital, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E","family":"Kasner","sequence":"additional","affiliation":[{"name":"Division of Vascular Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette D","family":"Lista","sequence":"additional","affiliation":[{"name":"DiaMedica Therapeutics Inc., Minnetonka, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"Volpi","sequence":"additional","affiliation":[{"name":"The Houston Methodist Institute for Academic Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J","family":"Kleinig","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Adelaide Hospital, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Cordato","sequence":"additional","affiliation":[{"name":"Department of Neurology, Liverpool Hospital, Liverpool, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M","family":"Dewey","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip MC","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8843-5890","authenticated-orcid":false,"given":"Carlos","family":"Garcia-Esperon","sequence":"additional","affiliation":[{"name":"Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital, University of Newcastle, Newcastle, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-0961","authenticated-orcid":false,"given":"Ramesh","family":"Sahathevan","sequence":"additional","affiliation":[{"name":"Deakin University and St. Vincent\u2019s Hospital Melbourne, Fitzroy, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tissa","family":"Wijeratne","sequence":"additional","affiliation":[{"name":"Department of Medicine and Neurology, Melbourne Medical School, The University of Melbourne and Western Health, Sunshine Hospital, St Albans, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Brisbane and Women\u2019s Hospital and the University of Queensland, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0518-5887","authenticated-orcid":false,"given":"Darshan","family":"Ghia","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8365-6907","authenticated-orcid":false,"given":"Geoffrey C","family":"Cloud","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Alfred Hospital, Prahran, Victoria and Department of Neuroscience, School of Translational Medicine, Momash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Giuffre","sequence":"additional","affiliation":[{"name":"University of Calgary, Departments of Pediatrics and Cardiology, Libin Cardiovascular Institute, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2734-5132","authenticated-orcid":false,"given":"Philip M","family":"Bath","sequence":"additional","affiliation":[{"name":"Stroke Trials Unit, Mental Health &amp; Clinical Neuroscience, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ReMEDy1 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.1420"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.122.040073"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2015-0240"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418821918"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.118117"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.55.11.1475"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22404"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/159750"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088440"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-5391.2012.01167.x"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1461"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520943452"},{"key":"e_1_3_3_14_2","first-page":"694","article-title":"Tissue kallikrein reduces oxidative stress and attenuates cerebral ischemia\/reperfusion injury in rats","volume":"387","author":"Zhu H","year":"2009","unstructured":"Zhu H, Li Y, Hua Y, et al. Tissue kallikrein reduces oxidative stress and attenuates cerebral ischemia\/reperfusion injury in rats. Biochem Biophys Res Commun 2009; 387: 694\u2013700.","journal-title":"Biochem Biophys Res Commun"},{"key":"e_1_3_3_15_2","first-page":"548","article-title":"Tissue kallikrein reduces inflammatory responses in cerebral ischemia\/reperfusion injury through inhibition of TLR4\/NF-\u03baB signaling pathway in rats","volume":"411","author":"Zhu H","year":"2011","unstructured":"Zhu H, Wang Z, Ma C, et al. Tissue kallikrein reduces inflammatory responses in cerebral ischemia\/reperfusion injury through inhibition of TLR4\/NF-\u03baB signaling pathway in rats. Biochem Biophys Res Commun 2011; 411: 548\u2013554.","journal-title":"Biochem Biophys Res Commun"},{"key":"e_1_3_3_16_2","first-page":"944","article-title":"Effects of human tissue kallikrein on cerebral blood flow and infarct volume in a rat model of focal cerebral ischemia","volume":"32","author":"Ma J","year":"2005","unstructured":"Ma J, Wang Q, Li H, et al. Effects of human tissue kallikrein on cerebral blood flow and infarct volume in a rat model of focal cerebral ischemia. Clin Exp Pharmacol Physiol 2005; 32: 944\u2013949.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"e_1_3_3_17_2","first-page":"87","article-title":"Tissue kallikrein attenuates blood-brain barrier injury in a rat model of focal cerebral ischemia\/reperfusion","volume":"480","author":"Zhang Y","year":"2010","unstructured":"Zhang Y, Ma C, Liu C, et al. Tissue kallikrein attenuates blood-brain barrier injury in a rat model of focal cerebral ischemia\/reperfusion. Neurosci Lett 2010; 480: 87\u201391.","journal-title":"Neurosci Lett"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.03.032"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5289715"},{"key":"e_1_3_3_20_2","article-title":"Around 9% of patients with ischaemic stroke are suitable for thrombectomy","volume":"351","author":"Cohen DL","year":"2015","unstructured":"Cohen DL, Kearney R, Griffiths M, et al. Around 9% of patients with ischaemic stroke are suitable for thrombectomy. BMJ 2015; 351: h4607.","journal-title":"BMJ"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.013165"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7403104"},{"key":"e_1_3_3_23_2","first-page":"21","article-title":"Rates of intravenous thrombolysis and endovascular therapy for acute ischaemic stroke in China between 2019 and 2020","author":"Ye Q","year":"2022","unstructured":"Ye Q, Zhai F, Chao B, et al. Rates of intravenous thrombolysis and endovascular therapy for acute ischaemic stroke in China between 2019 and 2020. Lancet Reg Health West Pac 2022; 21.","journal-title":"Lancet Reg Health West Pac"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184266"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.028624"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107435"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1021\/js950488f"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.18203\/2349-3259.ijct20174861"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1534"}],"container-title":["International Journal of Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17474930251396480","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17474930251396480","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17474930251396480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:15:38Z","timestamp":1782386138000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17474930251396480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/17474930251396480"],"URL":"https:\/\/doi.org\/10.1177\/17474930251396480","relation":{},"ISSN":["1747-4930","1747-4949"],"issn-type":[{"value":"1747-4930","type":"print"},{"value":"1747-4949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]}}}